Cargando…
Nanotechnology-Based Combinatorial Anti-Glioblastoma Therapies: Moving from Terminal to Treatable
Aggressive glioblastoma (GBM) has no known treatment as a primary brain tumor. Since the cancer is so heterogeneous, an immunosuppressive tumor microenvironment (TME) exists, and the blood–brain barrier (BBB) prevents chemotherapeutic chemicals from reaching the central nervous system (CNS), therape...
Autores principales: | Barzegar Behrooz, Amir, Talaie, Zahra, Syahir, Amir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9415007/ https://www.ncbi.nlm.nih.gov/pubmed/36015322 http://dx.doi.org/10.3390/pharmaceutics14081697 |
Ejemplares similares
-
Could We Address the Interplay Between CD133, Wnt/β-Catenin, and TERT Signaling Pathways as a Potential Target for Glioblastoma Therapy?
por: Behrooz, Amir Barzegar, et al.
Publicado: (2021) -
Understanding Glioblastoma Biomarkers: Knocking a Mountain with a Hammer
por: Hassn Mesrati, Malak, et al.
Publicado: (2020) -
Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma
por: Barzegar Behrooz, Amir, et al.
Publicado: (2022) -
Treatable traits in asthma: moving beyond diagnostic labels
por: McDonald, Vanessa M, et al.
Publicado: (2022) -
Immunology Meets Bioengineering: Improving the Effectiveness of Glioblastoma Immunotherapy
por: Fekrirad, Zahra, et al.
Publicado: (2022)